Last reviewed · How we verify

Administration of Propess

Tel-Aviv Sourasky Medical Center · Phase 3 active Small molecule

Propess is a vaginal insert that delivers dinoprostone (prostaglandin E2) directly to the cervix to promote cervical ripening and labor induction.

Propess is a vaginal insert that delivers dinoprostone (prostaglandin E2) directly to the cervix to promote cervical ripening and labor induction. Used for Cervical ripening and labor induction in pregnant women at or near term with medical or obstetric indication for labor induction.

At a glance

Generic nameAdministration of Propess
SponsorTel-Aviv Sourasky Medical Center
Drug classProstaglandin E2 analog
TargetProstaglandin E receptor (EP receptor)
ModalitySmall molecule
Therapeutic areaObstetrics
PhasePhase 3

Mechanism of action

Propess contains dinoprostone, a naturally occurring prostaglandin E2 analog, which is released gradually from a polymer matrix insert placed in the vaginal fornix. The prostaglandin acts on cervical tissue to promote softening, effacement, and dilation of the cervix, facilitating the onset of labor. This localized delivery system provides sustained release over 12-24 hours, reducing systemic exposure compared to intravenous administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: